ブルーアイ病ワクチンの世界市場規模：製品タイプ別、用途別、地域範囲別、予測

ブルーアイ病ワクチンの市場規模と予測

ブルーアイ病ワクチンの市場規模は、2024年に32億米ドルと評価され、2026年から2032年の予測期間中にCAGR 3.93%で成長し、2032年には62億4,000万米ドルに達すると予測されています。

ブルーアイ病は、熱帯・亜熱帯地域の主要な養豚生産地である中部・中西部地域の風土病であるため、これらの風土病地域でブルーアイ病ワクチンが成長する可能性が高く、市場の成長につながります。ブルーアイ病ワクチンの世界市場レポートは、市場の全体的な評価を提供します。主要セグメント、動向、市場促進要因、抑制要因、競合情勢、市場で重要な役割を果たしている要因などを包括的に分析しています。

世界のブルーアイ病ワクチン市場の定義

ブルーアイ病は、哺乳豚や成長期の豚に発生するウイルス性疾患です。ブルーアイ病はブタ・ルブラウイルスによって引き起こされます。この病気は一般的に、脳炎、肺炎、呼吸器疾患によって識別されます。ブルーアイ病は成豚の繁殖不全や角膜混濁（角膜の瘢痕化を特徴とする眼障害）にも関連しています。

臨床症状や潰瘍は要因のひとつではあるが、他の病気と混同されることもあります。RNA、抗体、抗原の成分を検出するいくつかのメカニズムが開発されています。ブルーアイ病ウイルスでは2種類のワクチンが報告されています。ウマ、ラバ、ロバに使用できる有機ワクチン（一価および多価）と、効果のない一価の血清型4ワクチンが市販されていますが、現在は入手できません。サブユニットを含む新しいワクチンも試験されています。

ブルーアイ病ワクチンは、さまざまな感染症に苦しむ患者を支援し、患者ケアだけでなく全体的な業務効率を向上させる。病院内感染症の高い有病率や発症率は、衛生への関心の高まりや、住宅および商業・産業空間・ヘルスケアユニットの両方における感染症の蔓延に対する懸念の高まりによって、民間クリニックや病院への患者の流入が増加しています。これらの要因を総合すると、青色眼病ワクチンの需要は間もなく増加すると予測されます。

過去20年間、ブルーアイ病ワクチン市場は巨大な規模で成長してきたが、その間に企業構造や従業員の行動様式が変化し、多くの課題がもたらされました。ブルーアイ病ワクチンの世界市場は大きな変化を遂げつつあり、メーカーは仕事の構造を維持するために進化する必要があります。

ブルーアイ病ワクチンの世界市場概要

ブルーアイ病は、熱帯・亜熱帯地域の主要な養豚生産地である中部・中西部地域の風土病です。市場開拓の機会としては、新興国市場における認知度の向上と獣医療への支出の増加が挙げられます。これらの要因を総合すると、まもなくブルーアイ病ワクチンの需要が増加すると予測されます。

いくつかの予防ワクチン開発のための研究開発プログラムへの投資の増加や、種の健康に関連する規制機関がブルーアイ病治療のために提供するガイドラインは、世界のブルーアイ病ワクチン市場を刺激すると予想される主な要因です。技術的に高度なヘルスケアインフラの開発と、効果的なワクチン開発のための国際的な大学や著名なベンダーとの提携による進行中の研究プロジェクトは、世界のブルーアイ病ワクチン市場に有利な成長機会を提供するでしょう。

しかし、新興経済諸国を中心とする世界人口の大部分がまだこれらのワクチンを手にしていないため、世界のブルーアイ病ワクチン市場は課題に直面しています。外国人旅行者数の増加、人口増加を含む世界中への移住やその他の移動に伴い、これらのワクチンを広く製造する必要性が生じています。しかし、この分野の施設の運営・維持に関連する高コストは、市場成長の障害となると思われます。また、有資格の専門家の不足も市場成長の課題となります。

非構造化データの過剰が経済成長を鈍化させると予想されます。電子部品の相互接続の複雑化、世界の商品価格の下落、最近のCOVID-19の発生は、ブルーアイ病ワクチン市場に多くの課題をもたらしています。とはいえ、データセンターにおけるネットワーキングとストレージデバイスの需要増、スマートヘルスケアインフラの需要増、ヘルスケアアプリケーションにおけるロボット工学、センサーベースのデバイスの需要増は、予測期間中、ブルーアイ病ワクチン市場に大きなビジネスチャンスをもたらすと期待されています。

目次

第1章 ブルーアイ病ワクチンの世界市場導入

• 市場概要
• 調査範囲
• 前提条件

第2章 エグゼクティブサマリー

第3章 VERIFIED MARKET RESEARCHの調査手法

• データマイニング
• バリデーション
• 一次資料
• データソース一覧

第4章 ブルーアイ病ワクチンの世界市場展望

• 概要
• 市場力学
  • 促進要因
  • 抑制要因
  • 機会
• ポーターのファイブフォースモデル
• バリューチェーン分析

第5章 ブルーアイ病のワクチン世界市場：製品タイプ別

• 概要
• 生ワクチン
• 不活化ワクチン

第6章 ブルーアイ病ワクチンの世界市場：用途別

• 概要
• 子豚
• 成豚

第7章 ブルーアイ病ワクチンの世界市場：地域別

• 概要
• 北米
  • 米国
  • カナダ
  • メキシコ
• 欧州
  • ドイツ
  • 英国
  • フランス
  • その他欧州
• アジア太平洋
  • 中国
  • 日本
  • インド
  • その他アジア太平洋地域
• 世界のその他の地域
  • ラテンアメリカ
  • 中東・アフリカ

第8章 世界のブルーアイ病ワクチン市場の競合情勢

• 概要
• 各社の市場ランキング
• 主な開発戦略

第9章 企業プロファイル

• CAHIC
• Merial
• MSD Animal Health
• Chopper Biology
• Ceva
• ChengDu Tecbond
• Veterinary
• Ringpu Biology
• Qilu Animal
• DHN

第10章 付録

• 関連調査

Blue Eye Disease Vaccines Market Size And Forecast

Blue Eye Disease Vaccines Market size is valued at USD 3.2 Billion in 2024 and is projected to reach USD 6.24 Billion by 2032, growing at a CAGR of 3.93% during the forecast period 2026-2032.

The Blue Eye Disease is endemic in the central and west-central regions, which are the major swine-producing areas in tropical and subtropical areas, As a result of this, the potential for the growth of Blue Eye Disease vaccines in these endemic areas are higher, leading to the growth of the market. The Global Blue Eye Disease Vaccines Market report provides a holistic evaluation of the market. The report offers a comprehensive analysis of key segments, trends, drivers, restraints, competitive landscape, and factors that are playing a substantial role in the market.

Global Blue Eye Disease Vaccines Market Definition

Blue eye disease is a viral disease that occurs in nursing or growing pigs. Blue eye disease is caused by porcine rubulavirus. The disease is commonly identified by encephalitis, pneumonia, and respiratory diseases. Blue eye diseases are also connected to reproductive failure in adult pigs as well as corneal opacity, (eye disorder characterized by scarring of the cornea).

Although clinical symptoms and ulcers are a factor, they can be confused with other diseases. Several mechanisms have been developed to detect components of RNA, antibodies, and antigens. Two types of vaccines have been described with the Blue Eye Disease virus. Organic vaccines (monovalent and polyvalent) for use in horses, mules, and donkeys, are now available, as well as an ineffective, monovalent, serotype 4 vaccine, commercially available but no longer available. New vaccines, including subunits, have been tested.

Blue Eye Disease Vaccines aid patients suffering from different infections to improve overall operational efficiency as well as patient care. The high prevalence and incidence rates of hospital-acquired diseases increased focus on hygiene, and rising concerns over the spread of infectious diseases in both residential and commercial/industrial spaces/healthcare units, have led to an increase in patient flow to private clinics and hospitals. These factors, collectively, are projected to increase the demand for Blue Eye Disease Vaccines soon.

Over the past two decades, the Blue Eye Disease Vaccines Market has grown at an enormous scale, and over time it has brought many challenges with the change in the structure of the company and the way employees behave. The global Blue Eye Disease Vaccines Market is undergoing significant changes, as the manufacturers need to evolve in an attempt to keep the structure of their work.

Global Blue Eye Disease Vaccines Market Overview

The Blue Eye Disease is endemic in the central and west-central regions, which are the major swine-producing are in tropical and subtropical areas, As a result of this, the potential for the growth of Blue Eye Disease vaccines in these endemic areas are higher, leading to the growth of the market. Opportunities in the market include increasing awareness and a rise in expenditure on veterinary care in developing regions. These factors, collectively, are projected to increase the demand for Blue Eye Disease Vaccines shortly.

Increasing investment in R&D programs for the development of several preventive vaccines and guidelines provided by regulatory bodies associated with species health for Blue Eye Disease treatment are the major factors expected to stimulate the global Blue Eye Disease Vaccines Market. Developing technologically advanced healthcare infrastructure and ongoing research projects in association with international universities and prominent vendors for the development of effective vaccines will provide lucrative growth opportunities to the global Blue Eye Disease Vaccines Market.

However, the global Blue Eye Disease Vaccines Market faces challenges as a large percentage of the global population predominantly in developing economies is yet to have its hands on these vaccines. With the increase in the number of foreign travelers, cross migrations and other travels all over the world, including a growing population there is a need for the widespread manufacturing of these vaccines. However, the high costs associated with the operation and maintenance of facilities in the sector will be a hindrance to the growth of the market. In addition, the lack of qualified specialists will challenge the growth of the market.

Excess of unstructured data is expected to slow economic growth. The increasing complexity of interconnecting electronic components, the drop in global commodity prices, and the recent outbreak of COVID-19 have brought up many challenges to the Blue Eye Disease Vaccines Market. Nevertheless, rising demand for networking and storage devices in the data center, demand for smart healthcare infrastructure, robotics in healthcare applications, and sensor-based devices are expected to provide huge opportunities for the Blue Eye Disease Vaccines Market for the forecasted period.

Global Blue Eye Disease Vaccines Market: Segmentation Analysis

The Global Blue Eye Disease Vaccines Market is Segmented on the basis of Product Type, Application, and Geography.

Blue Eye Disease Vaccines Market, By Product Type

• Live Vaccines
• Killed Vaccines

Based on the Product Type, the market is segmented into Live Vaccines and Killed Vaccines. Live Vaccines are those vaccines in which the virus-causing disease is weakened and slowly develops body immunity. Killed Vaccines or Inactivated vaccines have grown viruses, bacteria, or pathogens which are then killed to stop the disease-producing agent.

Blue Eye Disease Vaccines Market, By Application

• Piglets
• Adult Pigs

Based on Application, the market is segmented into Piglets and Adult Pigs. Piglets are the largest contributor to the global market in 2019 in this segment and are very likely to continue the trend in the forecast period.

Blue Eye Disease Vaccines Market, By Geography

• North America
• Europe
• Asia Pacific
• Rest of the world

Based on regional analysis, the Global Blue Eye Disease Vaccines Market is classified into North America, Europe, Asia Pacific, and the Rest of the world. The North American region dominated the global market in 2019 followed by Europe and is expected to continue the trend in the forecast period. The Asia Pacific region is expected to grow at a rapid pace in the forecast period owing to rapid urbanization and industrialization with an increased investment towards smart & efficient technology and increased per capita income.

Key Players

The "Global Blue Eye Disease Vaccines Market" study report will provide valuable insight with an emphasis on the global market including some of the major players such as CAHIC, Merial, MSD Animal Health, Chopper Biology, Ceva, ChengDu Tecbond, Veterinary, Ringpu Biology, Qilu Animal and DHN.

Our market analysis also entails a section solely dedicated to such major players wherein our analysts provide an insight into the financial statements of all the major players, along with product benchmarking and SWOT analysis. The competitive landscape section also includes key development strategies, market share, and market ranking analysis of the above-mentioned players globally.

TABLE OF CONTENTS

1 INTRODUCTION OF GLOBAL BLUE EYE DISEASE VACCINES MARKET

• 1.1 Overview of the Market
• 1.2 Scope of Report
• 1.3 Assumptions

2 EXECUTIVE SUMMARY

3 RESEARCH METHODOLOGY OF VERIFIED MARKET RESEARCH

• 3.1 Data Mining
• 3.2 Validation
• 3.3 Primary Interviews
• 3.4 List of Data Sources

4 GLOBAL BLUE EYE DISEASE VACCINES MARKET OUTLOOK

• 4.1 Overview
• 4.2 Market Dynamics
  • 4.2.1 Drivers
  • 4.2.2 Restraints
  • 4.2.3 Opportunities
• 4.3 Porters Five Force Model
• 4.4 Value Chain Analysis

5 GLOBAL BLUE EYE DISEASE VACCINES MARKET, BY Product Type

• 5.1 Overview
• 5.2 Live Vaccines
• 5.3 Killed Vaccines

6 GLOBAL BLUE EYE DISEASE VACCINES MARKET, BY APPLICATION

• 6.1 Overview
• 6.2 Piglets
• 6.3 Adult Pigs

7 GLOBAL BLUE EYE DISEASE VACCINES MARKET, BY GEOGRAPHY

• 7.1 Overview
• 7.2 North America
  • 7.2.1 U.S.
  • 7.2.2 Canada
  • 7.2.3 Mexico
• 7.3 Europe
  • 7.3.1 Germany
  • 7.3.2 U.K.
  • 7.3.3 France
  • 7.3.4 Rest of Europe
• 7.4 Asia Pacific
  • 7.4.1 China
  • 7.4.2 Japan
  • 7.4.3 India
  • 7.4.4 Rest of Asia Pacific
• 7.5 Rest of the World
  • 7.5.1 Latin America
  • 7.5.2 Middle East & Africa

8 GLOBAL BLUE EYE DISEASE VACCINES MARKET COMPETITIVE LANDSCAPE

• 8.1 Overview
• 8.2 Company Market Ranking
• 8.3 Key Development Strategies

9 COMPANY PROFILES

• 9.1 CAHIC
  • 9.1.1 Overview
  • 9.1.2 Financial Performance
  • 9.1.3 Product Outlook
  • 9.1.4 Key Developments
• 9.2 Merial
  • 9.2.1 Overview
  • 9.2.2 Financial Performance
  • 9.2.3 Product Outlook
  • 9.2.4 Key Developments
• 9.3 MSD Animal Health
  • 9.3.1 Overview
  • 9.3.2 Financial Performance
  • 9.3.3 Product Outlook
  • 9.3.4 Key Developments
• 9.4 Chopper Biology
  • 9.4.1 Overview
  • 9.4.2 Financial Performance
  • 9.4.3 Product Outlook
  • 9.4.4 Key Developments
• 9.5 Ceva
  • 9.5.1 Overview
  • 9.5.2 Financial Performance
  • 9.5.3 Product Outlook
  • 9.5.4 Key Developments
• 9.6 ChengDu Tecbond
  • 9.6.1 Overview
  • 9.6.2 Financial Performance
  • 9.6.3 Product Outlook
  • 9.6.4 Key Developments
• 9.7 Veterinary
  • 9.7.1 Overview
  • 9.7.2 Financial Performance
  • 9.7.3 Product Outlook
  • 9.7.4 Key Developments
• 9.8 Ringpu Biology
  • 9.8.1 Overview
  • 9.8.2 Financial Performance
  • 9.8.3 Product Outlook
  • 9.8.4 Key Developments
• 9.9 Qilu Animal
  • 9.9.1 Overview
  • 9.9.2 Financial Performance
  • 9.9.3 Product Outlook
  • 9.9.4 Key Developments
• 9.10 DHN
  • 9.10.1 Overview
  • 9.10.2 Financial Performance
  • 9.10.3 Product Outlook
  • 9.10.4 Key Developments

10 Appendix

• 10.1 Related Research